Literature DB >> 11785686

Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats.

S Suarez1, L Garcia-Contreras, D Sarubbi, E Flanders, D O'Toole, J Smart, A J Hickey.   

Abstract

PURPOSE: Several low molecular weight amino acids have previously been reported to enable the oral delivery of proteins. In the present studies, the effect of H-MAP (hydroxy methyl amino propionic acid) on the pharmacokinetics (PK) and pharmacodynamics (PD) of porcine insulin delivered to the lungs of rats by spray-instillation (SI) has been determined.
METHODS: Aliquots (100 microl) of increasing doses of porcine insulin alone (0.26, 1.3, 2.6, 13, and 26 U/kg) or combined with increasing doses of H-MAP (5, 10, 16, and 25 mg/kg), at pH 7.2-7.6 were administered intratracheally to fasted anesthetized rats using a micro spray-instillator. Blood samples were collected from the jugular vein at specified intervals and the plasma concentrations of insulin and glucose were determined. The PK and PD of porcine insulin alone following subcutaneous (SC) administration of increasing doses were also determined.
RESULTS: The PK of insulin administered either by SI to the lungs or SC injection were absorption rate dependent, resulting in post-peak half-lives 10 to 25-fold greater than the reported intravenous elimination half-life (3 min). The relative bioavailability (F') of insulin administered alone by SI varied from 23.8 to 80% for the lowest and highest insulin dose, respectively. Co-administration of H-MAP and insulin to the lungs significantly changed the PK and PD of insulin in a dose dependent fashion. Maximum PK and PD responses were obtained at an H-MAP dose of 16 mg/kg and an insulin dose of 1.3 U/kg. At this combination, the relative bioavailability of insulin was increased more than 2.5 fold, maximum concentration (Cmax) increased 2-fold and the minimum plasma glucose concentration (%MPGC) was reduced more than 2-fold with respect to same dose of insulin alone. A greater total reduction in plasma glucose (%TRPG0-->t) was achieved for H-MAP/insulin combination (66+/-5%) compared to insulin alone (47+/-10 %).
CONCLUSION: H-MAP has potential for increasing the pulmonary bioavailability of insulin administered through the lungs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11785686     DOI: 10.1023/a:1013362227548

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Modeling absorption kinetics of subcutaneous injected soluble insulin.

Authors:  E Mosekilde; K S Jensen; C Binder; S Pramming; B Thorsteinsson
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

Review 2.  Role of the kidney in insulin metabolism and excretion.

Authors:  A H Rubenstein; I Spitz
Journal:  Diabetes       Date:  1968-03       Impact factor: 9.461

3.  Insulin across respiratory mucosae by aerosol delivery.

Authors:  F W Wigley; J H Londono; S H Wood; J C Shipp; R H Waldman
Journal:  Diabetes       Date:  1971-08       Impact factor: 9.461

4.  125I-insulin: kinetics of interaction with its receptors and rate of degradation in vivo.

Authors:  J C Sodoyez; F R Sodoyez-Goffaux; Y M Moris
Journal:  Am J Physiol       Date:  1980-07

5.  Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung.

Authors:  F Komada; S Iwakawa; N Yamamoto; H Sakakibara; K Okumura
Journal:  J Pharm Sci       Date:  1994-06       Impact factor: 3.534

6.  Fate of porcine and human insulin at the subcutaneous injection site. I. Degradation and absorption of insulins in the rat.

Authors:  K Okumura; F Komada; R Hori
Journal:  J Pharmacobiodyn       Date:  1985-01

7.  N-acylated alpha-amino acids as novel oral delivery agents for proteins.

Authors:  A Leone-Bay; N Santiago; D Achan; K Chaudhary; F DeMorin; L Falzarano; S Haas; S Kalbag; D Kaplan; H Leipold
Journal:  J Med Chem       Date:  1995-10-13       Impact factor: 7.446

8.  New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier.

Authors:  C Damgé; C Michel; M Aprahamian; P Couvreur
Journal:  Diabetes       Date:  1988-02       Impact factor: 9.461

9.  Pulmonary biotransformation of insulin in rat and rabbit.

Authors:  F Y Liu; D O Kildsig; A K Mitra
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

10.  Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors.

Authors:  M Takeyama; T Ishida; N Kokubu; F Komada; S Iwakawa; K Okumura; R Hori
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

View more
  6 in total

1.  Influence of absorption promoters on pulmonary insulin bioactivity.

Authors:  T Mahesh Kumar; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

2.  Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides.

Authors:  Alamdar Hussain; Quamrul H Majumder; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2006-12-07       Impact factor: 4.200

3.  Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats.

Authors:  Mathangi Gopalakrishnan; Sandra Suarez; Anthony J Hickey; Jogarao V S Gobburu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

4.  Insulin self-association: effects on lung disposition kinetics in the airways of the isolated perfused rat lung (IPRL).

Authors:  Yinuo Pang; Masahiro Sakagami; Peter R Byron
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

5.  Evaluation of novel particles as pulmonary delivery systems for insulin in rats.

Authors:  Lucila Garcia-Contreras; Tülin Morçöl; Steve J D Bell; Anthony J Hickey
Journal:  AAPS PharmSci       Date:  2003

6.  Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethyl-beta-cyclodextrin.

Authors:  Alamdar Hussain; Tianzhi Yang; Abdel-Azim Zaghloul; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.